Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

Visualizar Toda a Documentação

S8451

Sigma-Aldrich

Saquinavir mesylate

≥98% (HPLC), powder

Sinônimo(s):

(2S)-N1[(1S,2R)-3-[(3S,4aS,8aS)-3-[[(1,1-Dimethylethyl)amino]carbonyl]octahydro-2(1H)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]butanediamide methanesulfonate, Ro-31-8959

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(1)

About This Item

Fórmula empírica (Notação de Hill):
C38H50N6O5·CH4O3S
Número CAS:
149845-06-7
Peso molecular:
766.95
Número MDL:
MFCD00944907
Código UNSPSC:
12352200
ID de substância PubChem:
329824603
NACRES:
NA.77

Ensaio

≥98% (HPLC)

Formulário

powder

condição de armazenamento

desiccated

cor

white to tan

solubilidade

DMSO: ≥5 mg/mL

originador

Roche

temperatura de armazenamento

2-8°C

cadeia de caracteres SMILES

CS(O)(=O)=O.CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)[C@H](CC(N)=O)NC(=O)c4ccc5ccccc5n4

InChI

1S/C38H50N6O5.CH4O3S/c1-38(2,3)43-37(49)32-20-26-14-7-8-15-27(26)22-44(32)23-33(45)30(19-24-11-5-4-6-12-24)41-36(48)31(21-34(39)46)42-35(47)29-18-17-25-13-9-10-16-28(25)40-29;1-5(2,3)4/h4-6,9-13,16-18,26-27,30-33,45H,7-8,14-15,19-23H2,1-3H3,(H2,39,46)(H,41,48)(H,42,47)(H,43,49);1H3,(H,2,3,4)/t26-,27+,30-,31-,32-,33+;/m0./s1

chave InChI

IRHXGOXEBNJUSN-YOXDLBRISA-N

Procurando produtos similares? Visita Guia de comparação de produtos

Categorias relacionadas

Descrição geral

Saquinavir is a peptidomimetic hydroxyethylamine inhibitor, which is used to treat human immunodeficiency virus (HIV) infection.

Aplicação

Saquinavir mesylate may be used in cell signaling and immunology studies.

Ações bioquímicas/fisiológicas

Saquinavir is an HIV Protease Inhibitor used in antiretroviral therapy.
Saquinavir is an HIV Protease Inhibitor used in antiretroviral therapy. It inhibits both HIV-1 and HIV-2 proteases. Studies have also looked at saquinavir as a possible anti-cancer agent.

Características e benefícios

This compound is a featured product for ADME Tox research. Click here to discover more featured ADME Tox products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by Roche. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number
104M4760V
032M4749V
021M4741V

Não está vendo a versão correta?

Se precisar de uma versão específica, você pode procurar um certificado específico pelo número do lote ou da remessa.

Pesquise por COA

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Os clientes também visualizaram

Slide 1 of 5

1 of 5

Lopinavir ≥98% (HPLC)

Sigma-Aldrich

SML1222

Lopinavir

Lonafarnib ≥98% (HPLC)

Sigma-Aldrich

SML1457

Lonafarnib

Cepharanthine ≥95% (HPLC)

Sigma-Aldrich

SML1269

Cepharanthine

vibrant-m

Y0001498

Lopinavir

Lamivudine Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1365

Lamivudine

Can inhibition of proteasomes or NF-kappaB help control idiopathic nephrotic syndrome?
Scott E Wenderfer
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 27(5), 1698-1701 (2012-05-02)
Rowena E Martin et al.
Antimicrobial agents and chemotherapy, 56(5), 2283-2289 (2012-02-23)
The antiretroviral protease inhibitors (APIs) ritonavir, saquinavir, and lopinavir, used to treat HIV infection, inhibit the growth of Plasmodium falciparum at clinically relevant concentrations. Moreover, it has been reported that these APIs potentiate the activity of chloroquine (CQ) against this
Rosanna Coppo et al.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 27(5), 1902-1910 (2012-03-21)
Some difficult cases of idiopathic nephrotic syndrome (NS) have been treated with a HIV protease inhibitor provided with proteasome-inhibiting activity. The objective of this study was to limit nuclear factor κB (NF-κB) activation which is up-regulated in these patients, aiming
Ana Beloqui et al.
Journal of controlled release : official journal of the Controlled Release Society, 166(2), 115-123 (2012-12-26)
The aims of this work were (i) to evaluate the potential of nanostructured lipid carriers (NLCs) as a tool to enhance the oral bioavailability of poorly soluble compounds using saquinavir (SQV), a BCS class IV drug and P-gp substrate as
Danijela Maksimovic-Ivanic et al.
Immunologic research, 52(1-2), 157-168 (2012-03-13)
Development of resistance to TRAIL-induced toxicity is one of the strategies used from tumor cells to escape destruction from the immune system. This process may occur through aberrant expression of functional receptors, overexpression of decoy receptors on tumor cell membrane
Exibir todos os documentos relacionados

Conteúdo relacionado

Discover Bioactive Small Molecules for Immunology Research

We offer agonists, antagonists, modulators and other bioactive small molecules for immune system signaling target identification and validation, as well as a variety of antibiotics, antivirals, and antifungals.

Discover Bioactive Small Molecules for ADME/Tox

Discover Bioactive Small Molecules for ADME/Tox

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica